Drugs / ALTIRATINIB
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02228811 | Jun 2014 → Nov 2017 | NTRK fusion positive cancer, metastatic neoplasm | Deciphera Pharmaceuticals, LLC | Terminated | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2014-11-20 | Deciphera Pharmaceuticals, LLC | Results Deciphera Pharmaceuticals Presents Data on Altiratinib (DCC-2701), an Advanced Multi-targeted Kinase Inhibitor, at 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics deciphera.com ↗
In in vivo studies, altiratinib was shown to inhibit tumor growth, evasive vascularization, invasion and/or metastasis. |
| 2014-11-17 | Deciphera Pharmaceuticals, LLC | Results Deciphera Pharmaceuticals Presents Data on Altiratinib (DCC-2701) that Demonstrated Inhibition of Tumor Growth and Invasion in Bevacizumab Resistant Glioblastoma deciphera.com ↗
today announced the presentation of preclinical data that demonstrated that altiratinib (DCC-2701) inhibited tumor growth and invasion in a bevacizumab resistant glioblastoma mouse model. |
All press releases naming this drug 5 releases
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ALTIRATINIB | ChEMBL registry synonym — accepted as the source's own label CHEMBL3545365 ↗ |
| Known as | DCC-2701 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02228811 ↗ |
| Known as | DP-5164 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3545365 ↗ |
| Action | Inhibit | “Vascular endothelial growth factor receptor 2 inhibitor” CHEMBL3545365 ↗2“Hepatocyte growth factor receptor inhibitor” CHEMBL3545365 ↗ “Tyrosine-protein kinase TIE-2 inhibitor” CHEMBL3545365 ↗ |
| Modality | Small molecule | — CHEMBL3545365 ↗ |
| Route | Oral | “given orally BID (twice daily)” NCT02228811 ↗ |
| Target | KDR | “Vascular endothelial growth factor receptor 2 inhibitor” CHEMBL3545365 ↗ |
| Target | MET | “Hepatocyte growth factor receptor inhibitor” CHEMBL3545365 ↗ |
| Target | TEK | “Tyrosine-protein kinase TIE-2 inhibitor” CHEMBL3545365 ↗ |